
## **Amendments to the Claims**

1. (Currently amended) A MAG expression promoter method of promoting expression of MAG comprising administering a compound of the formula (I)



wherein

R<sup>1</sup> is a hydrogen atom, a halogen atom, an alkyl

group or an alkoxy group;

 $R^2$  and  $R^3$  are the same or different and each is a

hydrogen atom or an alkyl group;

R<sup>4</sup> is an alkyl group, -COOH, -COOR<sup>5</sup>, -CONR<sup>6</sup>R<sup>7</sup>,

-CH<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CH<sub>2</sub>OH or -CH<sub>2</sub>OR<sup>8</sup>;

wherein  $R^5$  and  $R^6$ - $R^8$  are each an alkyl group, and  $R^6$  and  $R^7$  are the same or different and each is a hydrogen atom or an alkyl group, or  $R^6$  and  $R^7$  in combination form imidazole together with the adjacent nitrogen atom;

A is 
$$-CH(OH)$$
-,  $-C(=O)$ - or  $-CH_2$ -; and

$$Z$$
 is =CH- or =N-,

an optically active form thereof or a pharmaceutically acceptable salt thereof to a mammal.

## 2-9. (Cancel)

10. (Currently amended) A method for prophylaxis and/or therapy of a disease eaused by hypomyelination promoting a myelination of axon, which method comprises administering a compound of the formula (I)

$$\begin{array}{c|c}
R^{1} \\
\hline
 & \\
R^{2}
\end{array}$$

$$\begin{array}{c|c}
R^{2} \\
\hline
 & \\
R^{4}
\end{array}$$
(I)

wherein

R<sup>1</sup> is a hydrogen atom, a halogen atom, an alkyl

group or an alkoxy group;

 $R^2$  and  $R^3$  are the same or different and each is a

hydrogen atom or an alkyl group;

R<sup>4</sup> is an alkyl group, -COOH, -COOR<sup>5</sup>, -CONR<sup>6</sup>R<sup>7</sup>,

-CH<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CH<sub>2</sub>OH or -CH<sub>2</sub>OR<sup>8</sup>;

wherein  $R^5$  and  $R^6$ - $R^8$  are each an alkyl group, and  $R^6$  and  $R^7$  are the same or different and each is a hydrogen atom or an alkyl group, or  $R^6$  and  $R^7$  in combination form imidazole together with the adjacent nitrogen atom;

A is 
$$-CH(OH)$$
-,  $-C(=O)$ - or  $-CH_2$ -; and

$$Z$$
 is =CH- or =N-,

an optically active form thereof or a pharmaceutically acceptable salt thereof to-mammals inclusive of human a mammal.

- 11. (Original) The method of claim 10, wherein, in the formula (I), R<sup>1</sup> is a halogen atom, an alkyl group or an alkoxy group.
- 12. (Currently amended) A method for prophylaxis and/or therapy of a disease eaused by hypomyelination promoting a myelination of axon, which method comprises administering 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid, an optically active form thereof or a pharmaceutically acceptable salt thereof to mammals inclusive of human a mammal.

13. (Currently amended) A method for-prophylaxis and/or therapy of a disease mainly presenting dysmyelination or demyelination promoting a myelination of axon, which method comprises administering a compound of the formula (I)

wherein

R<sup>1</sup> is a hydrogen atom, a halogen atom, an alkyl

group or an alkoxy group;

 $R^2$  and  $R^3$  are the same or different and each is a

hydrogen atom or an alkyl group;

R<sup>4</sup> is an alkyl group, -COOH, -COOR<sup>5</sup>, -CONR<sup>6</sup>R<sup>7</sup>,

-CH<sub>2</sub>NR<sup>6</sup>R<sup>7</sup>, -CH<sub>2</sub>OH or -CH<sub>2</sub>OR<sup>8</sup>;

wherein  $R^5$  and  $R^6$ - $R^8$  are each an alkyl group, and  $R^6$  and  $R^7$  are the same or different and each is a hydrogen atom or an alkyl group, or  $R^6$  and  $R^7$  in combination form imidazole together with the adjacent nitrogen atom;

Z is 
$$=$$
CH- or  $=$ N-,

an optically active form thereof or a pharmaceutically acceptable salt thereof to mammals inclusive of human a mammal.

- 14. (Original) The method of claim 13, wherein, in the formula (I), R<sup>1</sup> is a halogen atom, an alkyl group or an alkoxy group.
- 15. (Currently amended) A method for prophylaxis and/or therapy of a disease mainly presenting dysmyelination or demyelination promoting a myelination of axon, which method comprises administering 4-[α-hydroxy-5-(1-imidazolyl)-2-methylbenzyl]-3,5-dimethylbenzoic acid, an optically active form thereof or a pharmaceutically acceptable salt thereof to mammals inclusive of human a mammal.

16-18. (Cancel)

19-30. (Cancelled)

31-36. (Cancel)

- 37. (New) The method of claim 10, wherein the mammal is a human.
- 38. (New) The method of claim 12, wherein the mammal is a human.
- 39. (New) The method of claim 13, wherein the mammal is a human.
- 40. (New) The method of claim 15, wherein the mammal is a human.